The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform


Argos in The News

Argos Therapeutics to Host Review of the Current Clinical Research Landscape in Kidney Cancer Following the 40th Congress of the European Society for Medical Oncology, With Insights From Dr. Charles Drake of Johns Hopkins Sidney Kimmel Cancer Center
Read more

Argos Therapeutics to Participate in 2015 Stem Cell Meeting on the Mesa
Read more

Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics
Read more

> More News & Events >>>


When Our Company Was Founded


First Arcelis product (AGS-003) clinical trial initiated in mRCC


Phase 3 mRCC ADAPT Study Launched


Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC